Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

Raises Full-Year Adjusted Diluted EPS Guidance and Revises Assumptions; Third-Quarter Reported Diluted EPS Grew 13.2% to $2.23, Adjusted Diluted EPS Grew 17.3% to $2.24, and by 13.1% excluding currencySTAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc. (PMI) (NYSE: PM) today announces its 2025 third quarter results.1 "In the third quarter, we continued to invest in the growth of our increasingly profitable smoke-free business, while achieving record quarterly smoke-free gross profit and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "Our global smoke-free portfolio is outgrowing the industry by a clear margin, driving positive total volumes, strong top-line growth and impressive margin expansion." "We are on track to exceed our industry-leading 2024-26 growth targets and upgrade our 2025 full-year adjusted diluted EPS forecast." _________________________ 1 Explanation of PMI's use of non-GAAP measures cited in this document and reconciliations to the most directly comparable U.S. GAAP measures can be found in the “Non-GAAP Measures, Glossary and Explanatory Notes” section of this release, in Exhibit 99.2 to the company's Form 8-K dated October 21, 2025, and at www.pmi.com/2025Q3earnings. Results Highlights - Third-Quarter 2025 Smoke-free business (SFB): Our smoke-free business accounted for 41% of total net revenues (up by 2.9pp vs. Q3 last year) and over 42% of total gross profit (up by 2.5pp vs. Q3 last year). Our smoke-free products (SFP) are now available in 100 markets, nearly half of which have at least two of our three flagship brands (IQOS, ZYN and VEEV) available for sale. Our SFB continues to deliver superior performance, with shipment volumes up by 16.6%, net revenues growing by 17.7% (13.9% organically) and gross profit increasing by 19.5% (14.8% organically). Inhalable smoke-free products: IQOS continues to strengthen its overall position as the second largest nicotine ‘brand’ in markets where present (gaining 0.9pp of combined cigarette and HTU industry volumes to reach 9.1% share) and is driving the growth of the global heat-not-burn category, where PMI holds approximately 76% volume share. HTU adjusted in-market sales (IMS) volume, which excludes the net impact of estimated distributor and wholesaler inventory movements, grew by 9.0% against a strong prior year comparator. In Japan, notwithstanding a significant intensifying of competition, adjusted IMS grew by an estimated 6.0%, with IQOS continuing to hold its share of the heat-not-burn category. IQOS HTU adjusted market share of total nicotine increased by 1.8pp to 31.7%. The overall category exceeds 50% of total nicotine offtake share in 14 out of 20 major cities and 10 prefectures. In Europe, adjusted IMS reached a record 15 billion units and grew by an estimated 7.3%, with a further acceleration in Italy and strong growth in many markets, notably Greece, Spain and Romania. As we continue to roll out the ILUMA i device, we are continuously innovating on IQOS consumables, with DELIA sourcing incremental users from new cohorts of legal-age smokers, and LEVIA growing its appeal among legal-age vapers. IQOS HTU adjusted market share increased by 1.2pp to 10.7%. Outside Europe and Japan, strong adjusted IMS growth continued and offtake share increased in key cities across the globe, including Cairo, Mexico City, Tunis, Riyadh, Seoul, Jakarta and Kuala Lumpur. In Indonesia, the broader roll-out of BONDS by IQOS continues as a complementary offer to IQOS ILUMA with promising early results. In the e-vapor category, VEEV continued its increasingly profitable growth, and is now available in 46 markets. Shipment volumes grew by 91.0%, driven by Europe and Indonesia. Within the closed pods segment, VEEV holds a top 3 position in 15 markets, including the #1 position in 8 markets. PMI remains committed to building and commercializing the brand in a focused, responsible and profitable manner as VEEV increasingly sources from non-IQOS legal-age nicotine users. Oral SFP: Shipment volume increased by 16.9% in pouch or pouch equivalents (20.2% in cans), fueled by nicotine pouches, which more than doubled outside the U.S. and Nordics, and in the U.S. grew by 37% to 205 million cans. In the U.S., ZYN accelerated its offtake growth to a remarkable 39% in Q3 as estimated by Nielsen, also driving category growth to over 40%. The growth of ZYN was supported by a wide range of commercial activities to further enhance the strength and presence of the brand, and ensure competitive price positioning following several quarters of reduced activity due to supply constraints. In addition, we implemented select short-term 'relaunch' promotions to mark ZYN's return to full availability and boost trial among legal-age smokers. While this had an impact on Americas Region Q3 net revenue and operating income growth, we expect U.S. ZYN to remain best-in-class in terms of profitability for the group, reinforcing the attractive outlook for the category. The growth of the international nicotine pouch business was fueled by strong offtake and geographic expansion. Our focus remains on switching legal-age smokers with a relevant product portfolio. Pakistan, the UK, Poland, and South Africa delivered strong performances. Following further launches, ZYN is now available in 46 international markets. Combustibles: Notwithstanding expected lower volumes, net revenues grew by 4.3% (up 1.0% organically) fueled by high single-digit pricing, partly offset by negative mix dynamics. This drove another quarter of robust gross profit growth of 7.7% (4.8% organically). Marlboro reached 10.9% category share, its highest quarterly market share since the 2008 spin. Our overall cigarette category share was broadly stable for the first nine-months. Dividend: Increased regular quarterly dividend by 8.9% to $1.47 per share, or an annualized $5.88 per share. Performance Highlights - Third-Quarter 2025 Total PMI SFP HTU Oral SFP E-vapor2 Cigarettes Total Shipment Volume (units bn) 204.9 46.9 40.8 5.2 0.9 157.9 vs. Q3 2024 0.7% 16.6% 15.5% 16.9% 91.0% (3.2)% PMI Smoke-Free Business Combustibles Net Revenues ($ bn) $10.8 $4.4 $6.4 reported vs. Q3 2024 9.4% 17.7% 4.3% organic vs. Q3 2024 5.9% 13.9% 1.0% Gross Profit ($ bn) $7.4 $3.1 $4.3 reported vs. Q3 2024 12.4% 19.5% 7.7% organic vs. Q3 2024 8.7% 14.8% 4.8% Operating Income ($ bn) $4.3 reported vs. Q3 2024 16.7% organic vs. Q3 2024 7.5% Reported Diluted EPS Adjusting Items3 Adjusted Diluted EPS Currency Impact Adj. Diluted EPS ex. Currency EPS $2.23 $(0.01) $2.24 $0.08 $2.16 vs. Q3 2024 13.2% 17.3% 13.1% Performance Highlights - First Nine Months 2025 Total PMI SFP HTU Oral SFP E-vapor2 Cigarettes Total Shipment Volume (units bn) 592.7 134.8 116.7 15.7 2.4 457.9 vs. YTD 2024 1.8% 14.3% 12.2% 22.5% +100% (1.3)% PMI Smoke-Free Business Combustibles Net Revenues ($ bn) $30.3 $12.5 $17.8 reported vs. YTD 2024 7.5% 16.0% 2.2% organic vs. YTD 2024 7.5% 16.1% 2.2% Gross Profit ($ bn) $20.5 $8.7 $11.7 reported vs. YTD 2024 12.1% 23.3% 5.1% organic vs. YTD 2024 11.8% 22.5% 4.9% Operating Income ($ bn) $11.5 reported vs. YTD 2024 13.6% organic vs. YTD 2024 12.5% Reported Diluted EPS Adjusting Items3 Adjusted Diluted EPS Currency Impact Adj. Diluted EPS ex. Currency EPS $5.89 $0.06 $5.83 $0.02 $5.81 vs. YTD 2024 20.4% 16.4% 16.0% _________________________ 2 One milliliter of e-vapor liquid equivalent to 10 units; 2024 volume of e-vapor in billions of units: Q1 0.3, Q2 0.4, Q3 0.5, Q4 0.5 3 For a list of adjusting items refer to additional information section of this release Note: Sums might not foot to total due to rounding. 2025 Full-Year Forecast Full-Year 2025 Forecast 2024 Growth Reported Diluted EPS $7.39 - $7.49 $ 4.52 Adjustments: Restructuring charges(1) 0.13 0.10 Impairment of goodwill and other intangibles 0.03 0.01 Amortization of intangibles(2) 0.50 0.40 Germany excise tax classification litigation charge 0.10 — RBH (Canada) Plan Implementation, including dividend income, net (0.10) — Impairment of Wellness & Healthcare related equity investment 0.09 — Income tax impact associated with Swedish Match AB financing (0.24) 0.14 Fair value adjustment for equity security investments (0.33) (0.27) Tax items (0.11) (0.03) Other 2024 adjustments(3) — 1.70 Total Adjustments 0.07 2.05 Adjusted Diluted EPS $7.46 - $7.56 $ 6.57 13.5% - 15.1% Less: Currency 0.10 Adjusted Diluted EPS, excluding currency $7.36 - $7.46 $ 6.57 12.0% - 13.5% (1) 2025 amount reflects pre-tax restructuring charges of $243 million ($200 million net of income tax) incurred in Q2 with respect to manufacturing footprint optimization in Germany (2) See forecast assumptions for details (3) Includes $0.13 loss on sale of Vectura Group, $0.03 Egypt sales tax charge, $0.05 Megapolis localization tax impact, $1.49 impairment related to the RBH equity investment Reported diluted EPS is forecast to be in a range of $7.39 to $7.49, at prevailing exchange rates, versus reported diluted EPS of $4.52 in 2024. Excluding a total 2025 adjustment of $0.07 per share, this forecast represents a projected increase of 13.5% to 15.1% versus adjusted diluted EPS of $6.57 in 2024. Also excluding a favorable currency impact of $0.10, at prevailing exchange rates, this forecast represents a projected increase of 12.0% to 13.5% versus adjusted diluted EPS of $6.57 in 2024, as outlined in the above table. 2025 Full-Year Forecast Assumptions This forecast assumes: An estimated total international industry volume decline of around 1% for cigarettes and HTUs, excluding China and the U.S.; Total cigarette and smoke-free product shipment volume growth for PMI of around 1%. We expect smoke-free product volume growth of 12% to 14%, partly offset by cigarette volume declines of around 2%. SFP volume growth continues to assume 10% to 12% growth in HTU adjusted IMS volumes, and U.S. nicotine pouch second-half shipment growth broadly in-line with offtake growth before trade inventory movements. Net revenue growth of around 6% to 8% on an organic basis; Organic operating income growth of 10% to 11.5%, including the impact of higher U.S. investments; Full-year amortization of acquired intangibles of $0.50 per share, including the amortization of IQOS commercialization rights in the U.S. related to the agreement to end our commercial relationship with Altria Group, Inc. covering IQOS in the U.S.; An effective tax rate, excluding discrete tax events, of around 22%; Operating cash flow of more than $11.5 billion at prevailing exchange rates, subject to year-end working capital requirements; this now includes dividend income from our deconsolidated Canadian affiliate. Capital expenditures of around $1.6 billion, almost entirely due to investments supporting the smoke-free business; Further net debt to adjusted EBITDA ratio improvement as we continue to target a ratio of around 2x by the end of 2026; and No share repurchases in 2025. Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections. New Segment Reporting With our smoke-free business now operating at scale across our regions, including substantial growth from our U.S. business, PMI plans to implement an evolved organizational model with two primary business units: International and U.S. The updated organizational structure is designed to enhance our agility and to support our journey to become a smoke-free company under the leadership of CEO Jacek Olczak. This change is scheduled for implementation effective January 1, 2026, and as a result we anticipate realigning our reportable segments. The current four geographic segments will be replaced with three new segments: International Smoke-Free, International Combustibles, and U.S. The company plans to report its financial results based on the new segments as of the first quarter of 2026. In the weeks following our 2025 full-year earnings announcement, the company plans to disclose select historical financial information for the 2023 to 2025 period based on the new segments. Conference CallRead the full story here

Philip Morris International Reports 2025 Third-Quarter & First Nine-Months Results

Інші новини компанії